Cargando…

Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report

Immune checkpoint inhibitors have been rapidly developed for lung cancer therapy and major clinical guidelines have recommended them as the optimal first-line treatment for PD-L1-positive advanced lung cancer. Unfortunately, there is a lack of efficient prediction tools for the occurrence of immune-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Tingting, Wang, Zhisheng, Liu, Xinlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935992/
https://www.ncbi.nlm.nih.gov/pubmed/36800626
http://dx.doi.org/10.1097/MD.0000000000032731